Gas-liquid interfaces in gastrointestinal contents

Gas-liquid interfaces in gastrointestinal contents represent a physical pharmacological target rather than a specific biological molecule like a receptor or enzyme. In the digestive tract, gas produced by bacterial fermentation or swallowed air can become trapped in liquid or mucus, forming a stable foam that leads to symptoms of bloating, pressure, and abdominal pain (PubMed, PMID: 10403580). This target is characterized by the surface tension that maintains the integrity of these small gas bubbles within the gut lumen. Drugs such as simethicone target these interfaces directly by acting as surfactants that lower surface tension. This physical change causes the small, trapped bubbles to break and coalesce into larger gas pockets, facilitating their expulsion from the body via belching or flatulence (StatPearls, 2023). Because the interaction is purely physical and occurs within the lumen of the gut, the drugs targeting these interfaces are generally not absorbed into the systemic circulation, resulting in a high safety profile and minimal systemic side effects (NIH, 2024).

Other names

Gastrointestinal gas-liquid interfaceIntestinal foamGastric gas bubblesGI gas-liquid boundary

Simethicone acts as an anti-foaming agent by reducing the surface tension of gas bubbles trapped within the gastrointestinal tract (StatPearls, 2023). This reduction in surface tension allows small, mucus-encapsulated bubbles to coalesce into larger volumes of gas, which are more easily eliminated through eructation or flatus (PubChem, 2024).